Portfolio Companies

Our investments are partnerships. We support visionary entrepreneurs with our capital and deep life sciences experience to realize medical breakthroughs for patients.

Filters

Funds

Therapeutic area

Product type

Allecra

Novel treatment to combat multi-drug resistant gram-negative bacterial infections

Alpha-9 Oncology

Targeted radiopharmaceuticals to treat cancer
Altrubio

Clinical stage biotech developing first-in-class Psgl-1 targeting biologics for autoimmune diseases
Antios

Novel antiviral therapies with lead program in HBV

AP Biosciences Inc.

Innovative antibody-based biotherapeutic developer
Apama (Acquired)

Ablation catheter for the untreated atrial fibrillation market

Atia

Accommodating intraocular lens replacement
Avenzo

Clinical-stage biotechnology company developing best-in-class oncology therapeutics targeting cell cycle control
Baronova

Non-surgical, non-pharmacologic devices to induce weight loss

Cardurion Pharmaceuticals

Developing novel drugs for major and rare cardiovascular diseases
Clover Biopharmaceuticals

I/O and vaccine platforms enabled by proprietary trimer tag technology
Curamir

Genetic medicine platform focused on microRNA therapeutics in oncology
Curatia

Interventional vascular products
Eccogene

Leading platform for novel drug discovery in obesity and metabolic disease
Ensoma

In vivo cell engineering platform for the treatment of cancer, autoimmune, and genetic diseases
Exsilio

Redosable, durable, mRNA-based genetic medicines delivered via lipid nanoparticles
Hemo

A leading interventional neurovascular company offering best-in-class products and services
Imperative

Interventional stroke innovations improving patient outcomes
Instylla

Next-generation liquid embolics for interventional radiology
Intrinsic

Spinal implants to prevent reherniation
LipoSeuticals

Enhancement of solubility and bioavailability through reformulation
Luqa (Acquired)

Leading specialty pharma in dermatology and aesthetics for the Chinese market

Odeon

Clinical-stage novel ADC for oncology

OncoMyx

Oncolytic virus immuno-oncology platform based on myxoma virus
Ostial

Aorto-ostial interventional technologies
Phanes Therapeutics

Innovative drug discovery in immuno-oncology and eye disease
Rejoni

A solution for the prevention of intrauterine adhesions
Reniva

Innovative therapeutic option to treat both functional and degenerative mitral diseases

Rgenta

Oral RNA-targeting drugs for incurable diseases
Sirius Therapeutics

Leading siRNA platform focusing on cardiovascular diseases
STRM.BIO

Novel gene therapies leveraging extracellular vesicles
Syndax (NASDAQ: SNDX)

Biopharma developing innovative cancer therapies
Tanvex (TWSE: 6541)

Vertically integrated biologic CDMO and biosimilar developer
Thermalin

Pioneer in next-generation insulin solutions

TRexBio

Advancing a portfolio of NextGen therapies to restore immune homeostasis
Truvic

Innovative solutions for peripheral thrombectomy
Tulavi

Neuro-modulation to prevent/treat peripheral and visceral diseases
Zenas (NASDAQ: ZBIO)

Developing a deep, clinical-stage portfolio of innovative therapeutics for broad inflammatory & immunology indications

Team

We are a partnership comprised of seasoned entrepreneurs and scientists, committed to investing our time and capital into a positive and lasting impact on human health.

view full team